LIGAND PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
LGND$314.16+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
| Common Stock · Additionalpaid-incapital · Accumulatedothercomprehensiveincome (loss) · Retained earnings · Totalstockholders’equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2022 | 16,951 | $17 | $147,590 | $(984) | $450,862 | $597,485 |
| Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes | 605 | 1 | 17,901 | — | — | 17,902 |
| Share-based compensation | — | — | 25,743 | — | — | 25,743 |
| Unrealized net gain on available-for-sale securities, net of tax | — | — | — | 167 | — | 167 |
| Final OmniAb Distribution | — | — | 1,665 | — | — | 1,665 |
| Final tax impact of OmniAb Distribution | — | — | 5,797 | — | — | 5,797 |
| Net income | — | — | — | — | 52,154 | 52,154 |
| Balance at December 31, 2023 | 17,556 | 18 | 198,696 | (817) | 503,016 | 700,913 |
| Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes | 1,190 | 2 | 60,452 | — | — | 60,454 |
| Issuance of common stock, net of commissions and fees | 360 | — | 37,140 | — | — | 37,140 |
| Share-based compensation | — | — | 41,089 | — | — | 41,089 |
| Unrealized net gain on available-for-sale securities, net of tax | — | — | — | 45 | — | 45 |
| Foreign currency translation adjustment, net of tax | — | — | — | (5,170) | — | (5,170) |
| Net loss | — | — | — | — | (4,032) | (4,032) |
| Balance at December 31, 2024 | 19,106 | 20 | 337,377 | (5,942) | 498,984 | 830,439 |
| ASU 2025-07 adoption: impact as of January 1, 2025 (Note 1) | — | — | — | — | (349) | (349) |
| Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes | 770 | — | 37,902 | — | — | 37,902 |
| Share repurchase in connection to the 2030 Notes (Note 9) | (102) | — | — | — | (15,000) | (15,000) |
| 2030 Notes hedge and warrant transactions, net of tax (Note 9) | — | — | (21,479) | — | — | (21,479) |
| Share-based compensation | — | — | 46,849 | — | — | 46,849 |
| Unrealized net gain on available-for-sale securities, net of tax | — | — | — | 181 | — | 181 |
| Foreign currency translation adjustment, net of tax | — | — | — | 14,216 | — | 14,216 |
| Net income | — | — | — | — | 124,453 | 124,453 |
| Balance at December 31, 2025 | 19,774 | $20 | $400,649 | $8,455 | $608,088 | $1,017,212 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.